Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Atreca Inc BCEL

Alternate Symbol(s):  COLUF

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.


PINL:BCEL - Post by User

Bullboard Posts
Comment by StocksLynxon Jul 26, 2013 11:30am
588 Views
Post# 21632530

RE:Stifel Nicolaus: hold rating for Colossus Minerals Inc.

RE:Stifel Nicolaus: hold rating for Colossus Minerals Inc.Thank you for the reference, but how can the NAV be $277.6 if they expect $40 million per year cash flow?
"A 200,000 ounce producer at $1400 gold at $1200 all-in cash costs means the company could potentially bring in $40 million cash flow a year. With a higher gold price, adjust accordingly. With higher production, potentially as much as 400,000+ ounces"

That would be a 7 years live time and Gold would have to stay at the average of $1400 for the period. With Gold at average $1900 we would only need a live time of 24 month to reach this "NAV" without any increase in production, with production increase we would only need a mine live time of 18 month to reach "NAV".

So I don't believe these NAV calculations at all. Any thought?
Bullboard Posts